ArticleDiscover nano2026
Biosynthesis of multifunctional silver nanoparticles using a Penicillium verrucosum RPF011 extract for antibacterial and anticancer applications.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study reports the green synthesis of silver nanoparticles (PV-Ag NPs) using a pigment-producing environmental fungus, Penicillium verrucosum (PV) RPF011, as a biological reducing and stabilizing agent. The formation of nanoparticles was initially evidenced by a distinct color change from light to dark brown, corresponding to the reduction of Ag⁺ ions, and was further confirmed by UV-visible spectroscopy showing a characteristic surface plasmon resonance peak at 433 nm. Fourier transform infrared (FTIR) analysis indicated the involvement of proteinaceous biomolecules in the reduction and capping processes, ensuring nanoparticle stability. X-ray diffraction (XRD) patterns revealed the crystalline nature of the synthesized nanoparticles, while high-resolution transmission electron microscopy (HR-TEM) analysis demonstrated that the PV-Ag NPs were predominantly spherical and polydisperse, with an average particle size of 78 ± 2 nm. The biologically synthesized nanoparticles exhibited potent antibacterial activity against clinically relevant pathogens, including Escherichia coli, Staphylococcus aureus, and Klebsiella pneumoniae. Furthermore, in vitro cytotoxicity assays revealed significant anticancer activity against the human lung carcinoma A549 cell line, with an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.